The latest price target for ADMA Biologics (NASDAQ:ADMA) was reported by HC Wainwright & Co. on November 8, 2024. The analyst firm set a price target for $26.00 expecting ADMA to rise to within 12 months (a possible 13.54% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for ADMA Biologics (NASDAQ:ADMA) was provided by HC Wainwright & Co., and ADMA Biologics maintained their buy rating.

The last upgrade for ADMA Biologics Inc happened on November 11, 2021 when Raymond James raised their price target to $5. Raymond James previously had an outperform for ADMA Biologics Inc.

There is no last downgrade for ADMA Biologics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on November 8, 2024 so you should expect the next rating to be made available sometime around November 8, 2025.

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $18.00 to $26.00. The current price ADMA Biologics (ADMA) is trading at is $22.90, which is within the analyst’s predicted range.